Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Latest News about Longeveron Recent news which mentions Longeveron Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results February 07, 2024 Tickers LGVN Tags Biotech Benzinga Penny Stocks From Benzinga Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ December 05, 2023 Tickers LGVN Tags Partner Content Longeveron LGVN From Benzinga Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ December 05, 2023 Tickers LGVN Tags General Market News Longeveron From Benzinga Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help? October 23, 2023 Tickers LGVN Tags Penny Stocks Benzinga Biotech From Benzinga Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial October 13, 2023 Tickers LGVN Tags Benzinga All Access Biotech Penny Stocks From Benzinga Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market September 11, 2023 Tickers AMGN LGVN MRNA Tags News AMGN Health Care From Benzinga Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For September 06, 2023 Tickers ABOS BIIB LGVN TLSA Tags Benzinga Biotech General From Benzinga Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases August 07, 2023 Tickers LGVN Tags Biotech Benzinga Penny Stocks From Benzinga Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 07, 2023 Tickers AMGN LGVN LLY Tags AMGN LLY Penny Stocks From Benzinga Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS July 11, 2023 Tickers LGVN Tags Benzinga Penny Stocks Interview From Benzinga HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes? June 28, 2023 Tickers LGVN Tags Penny Stocks Benzinga Biotech From Benzinga Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty April 20, 2023 Tickers LGVN Tags M&A Market News LGVN From Benzinga LGVN: Updating Model Following 2Q Results August 17, 2022 Tags Analyst Ratings Benzinga Partner Content From Benzinga Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry? August 09, 2022 Tickers ALZN BIIB LGVN SLDB Tags Tech Penny Stocks SLDB From Benzinga Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron August 02, 2022 Tickers ANVS LGVN LLY TECH Tags LGVN Longeveron Market News From Benzinga Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment July 28, 2022 Tickers BMY LGVN Tags General BMY Partner Content From Benzinga Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It June 15, 2022 Tickers LGVN SAVA STAB Tags Market News Longeveron LGVN From Benzinga Longeveron Partners With US Department Of Veterans Affairs For Its Phase 2 Alzheimer's Trial April 18, 2022 Tickers LGVN Tags Biotech Benzinga General From Benzinga Healthspan, Not Lifespan Should Be the Focus of Anti-Aging Research, Says Longeveron March 30, 2022 Tickers AMZN LGVN UBX Tags Biotech Benzinga General From Benzinga Longeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress March 14, 2022 Tickers LGVN Tags Press Releases Biotech Benzinga From Benzinga Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS) December 06, 2021 Tickers LGVN Tags General Small Cap Market News From Benzinga Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment October 04, 2021 Tickers LGVN Tags Health Care Penny Stocks Benzinga From Benzinga Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity September 29, 2021 Tickers LGVN Tags Health Care Benzinga Penny Stocks From Benzinga Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron September 15, 2021 Tickers JNJ LGVN MRN PFE Tags LGVN Longeveron Market News From Benzinga Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients September 09, 2021 Tickers LGVN Tags Market News LGVN Partner Content From Benzinga Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval July 07, 2021 Tags General Longeveron Partner Content From Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
